Aurobindo Pharma gets boost despite US FDA raised objections in its American subsidiarys inspection
The United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) at new injectable facility of Eugia US Manufacturing LLC (a step-down wholly owned subsidiary of Aurobindo Pharma Ltd.), situated at East Windsor, New Jersey, USA from December 11 to December 22, 2023, Aurobindo Pharma said in a statement on Sunday.
Aurobindo Pharma Share Price: Despite the US FDA raising multiuple objections during the inspection of its American stepdown subsidiary, Aurobindo Pharma shares were trading in positive territory on BSE on Tuesday.
The Aurobindo Pharma stock was trading higher by 1.12 per cent, or Rs 11.90, at Rs 1078.05, at 10:10 am on Tuesday.
"The United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) at new injectable facility of Eugia US Manufacturing LLC (a step-down wholly owned subsidiary of Aurobindo Pharma Ltd.), situated at East Windsor, New Jersey, USA from December 11 to December 22, 2023," the company said in a statement on Sunday.
The company further said, "The inspection closed with 10 observations. The observations are procedural in nature and will be responded to within the stipulated time. The plant is yet to start commercial operations."
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.